This website is for US healthcare professionals only. This website is not intended for patients.

Logo Horizontal
  • For HCPs
    • Prescribing information
    • Coverage restrictions
    • Prior authorization
    • Financial assistance
    • Sample requests
  • For Practices
    • Practice collaboration
    • Rep Management
  • For brands
    • Claim your page
    • Brand activation
    • Rep Connect
  • About
  • For HCPs
    • Prescribing information
    • Coverage restrictions
    • Prior authorization
    • Financial assistance
    • Sample requests
  • For Practices
    • Practice collaboration
    • Rep Management
  • For brands
    • Claim your page
    • Brand activation
    • Rep Connect
  • About
Compare drug alternatives

Humira® Alternatives

Humira®

(Adalimumab)
Humira
    Psoriatic Arthritis
  • Taltz®
  • Tremfya®
  • Stelara®
  • Cosentyx®
  • Skyrizi®
Prescription Only

Humira is a TNF-alpha inhibitor utilized to treat an extensive range of inflammatory conditions, including Rheumatoid Arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, and Ulcerative colitis. However, Humira can suppress the immune system's ability to fight off infections caused by bacteria, fungi, or viruses, potentially increasing the risk of developing certain types of cancer.

Humira is FDA approved for the following indications: Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn’s Disease, Ulcerative Arthritis, Plaque Psoriasis, Hidradenitis Suppurativa, and Uveitis.

Dupixent®

(Dupilumab)
Dupixent
    Psoriatic Arthritis
  • Taltz®
  • Tremfya®
  • Stelara®
  • Cosentyx®
  • Skyrizi®
Prescription Only

Dupixent is an injectable medication that is typically administered subcutaneously every other week to treat inflammatory conditions, such as asthma and eczema, among others. Injection site reactions and eye conditions are the most frequently reported side effects. The risk of infection is low with Dupixent, unlike other biologics.

Dupixent is FDA approved for the following indications: Atopic Dermatitis, Asthma, Chronic Rhinosinusitis with Nasal Polyposis, Eosinophilic Esophagitis, Prurigo Nodularis.

Dosage & Administration

Administration
Subcutaneous injection. Learn more.
Subcutaneous injection. Learn more.
Dosing
40 mg every other week
150 mg at Week 0, Week 4, and every 12 weeks thereafter.
Latin Shorthand
40 mg q2w
150 mg Week 0, 4 then q12w

Financial Assistance

Copay
$5
$5
Annual Cap
$14,000
$6,000
Assistance Expiration
Subject to change or discontinuation without notice (AbbVie discretion)
Generics
No lower-cost generic available
No lower-cost generic available

Popular alternatives

  • Humira® vs. Taltz®
  • Humira® vs. Tremfya®
  • Humira® vs. Stelara®
  • Humira® vs. Cosentyx®
  • Humira® vs. Skyrizi®

Relevant Resources

Humira
  • Dosage & Administration
  • Drug Label
  • Samples
  • Prior Authorization
  • Financial Assistance
Dupixent
  • Dosage & Administration
  • Drug Label
  • Samples
  • Prior Authorization
  • Financial Assistance
Company
About
Careers
Privacy
Terms
Contact
Solutions
Prescribing Information
Coverage Restrictions
Prior Authorization
Financial Assistance
Sample Requests
Practice Collaboration
Rep Management
Indications
Most Viewed
Angioedema
Atopic Dermatitis
Plaque Psoriasis
Psoriatic Arthritis
Rosacea
Compare drug alternatives
Providers
Log in
Sign up
Request demo
© PrescriberPoint, Inc. 2023. Help Patients, Increase Practice Efficiency.